Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medeon Biodesign's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 12.12%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medeon Biodesign's 3-Year ROIIC % or its related term are showing as below:
ROCO:6499's 3-Year ROIIC % is ranked better than 63.22% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 1.52
vs ROCO:6499: 12.12
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medeon Biodesign 3-Year ROIIC % Related Terms
Medeon Biodesign 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6499 vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medeon Biodesign (ROCO:6499) has a 3-Year ROIIC % of 12.12 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medeon Biodesign and its competitors. According to the industry distribution chart, Medeon Biodesign ranks #292 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 36.8%.
Is Medeon Biodesign's 3-Year ROIIC % too high?
Medeon Biodesign's current 3-Year ROIIC % is 12.12. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.52. Medeon Biodesign's value of 12.12 is 697.4% above this industry median. Based on the distribution chart, Medeon Biodesign ranks #292 out of 794 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medeon Biodesign has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #292 out of 794 companies for 3-Year ROIIC %. This puts Medeon Biodesign in the upper half of its industry. The industry median 3-Year ROIIC % is 1.52. Medeon Biodesign's value of 12.12 is 697.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.52, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current 3-Year ROIIC % of 12.12 is 697.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medeon Biodesign and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current 3-Year ROIIC % is 12.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Possible Value Trap. The stock's GF Value™ is NT$106.73, compared to a current price of NT$55.80 — trading 47.7% below its estimated fair value. The current 3-Year ROIIC % is 12.12 and 697.4% above the Medical Devices & Instruments industry median of 1.52. Medeon Biodesign's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current 3-Year ROIIC % is 12.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$55.80 is trading 47.7% below its estimated GF Value™ of NT$106.73.
GuruFocus considers Medeon Biodesign to be Possible Value Trap.
Key valuation signals for ROCO:6499:
3-Year ROIIC %: 12.12
GF Value™: NT$106.73 vs. price of NT$55.80 (47.7% below fair value)
Industry Position: 697.4% above the Medical Devices & Instruments median (#292 of 794)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
63GF Score
Get the complete analysis for ROCO:6499
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
